{
    "2021-05-12": [
        [
            {
                "time": "",
                "original_text": "9只创新高股获主力资金抢筹凯莱英净流入资金居首",
                "features": {
                    "keywords": [
                        "创新高",
                        "主力资金",
                        "凯莱英",
                        "净流入"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "大跌82%，市值蒸发逾3400亿，科技龙头再创新低！大消费板块牛股频现，能否持续跑赢大盘？ 连续下跌",
                "features": {
                    "keywords": [
                        "大跌",
                        "科技龙头",
                        "创新低",
                        "大消费",
                        "牛股",
                        "连续下跌"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "科技",
                        "消费"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "凯莱英(002821)2021年一季报点评：剔除汇率和激励影响后业绩符合预期",
                "features": {
                    "keywords": [
                        "凯莱英",
                        "一季报",
                        "业绩",
                        "符合预期",
                        "汇率",
                        "激励"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "高瓴资本概念股走势分化，健康元、凯莱英、海正药业、泰格医药强势上扬",
                "features": {
                    "keywords": [
                        "高瓴资本",
                        "概念股",
                        "走势分化",
                        "健康元",
                        "凯莱英",
                        "海正药业",
                        "泰格医药",
                        "强势上扬"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药行业2020年年报＆2021Q1季报小结及前瞻：业绩恢复强劲 高景气赛道表现亮眼",
                "features": {
                    "keywords": [
                        "医药行业",
                        "年报",
                        "季报",
                        "业绩恢复",
                        "高景气赛道",
                        "表现亮眼"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "中泰证券：国内CRO/CDMO行业全面恢复，把握具备长期成长性的板块优质公司",
                "features": {
                    "keywords": [
                        "中泰证券",
                        "CRO/CDMO",
                        "全面恢复",
                        "长期成长性",
                        "优质公司"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}